The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

This trial demonstrates that next-generation CD40L blocking antibodies can be used safely in HCT recipients and supports initial clinical efficacy in the prevention of GVHD. Further study is needed in ...

It's early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

The work focuses on the interaction of B cells and T cells in the body's immune system via two proteins—CD40 on B cells and CD40L on T cells—in an immune deficiency disease called X-linked ...

Sanofi has posted encouraging results with one of its mid-stage candidates for multiple sclerosis, anti-CD40L antibody frexalimab, and says it plans to move the drug into a phase 3 programme next ...

Eledon Pharmaceuticals, Inc. ( ($ELDN) ) has released its Q4 earnings. Here is a breakdown of the information Eledon Pharmaceuticals, Inc.

Detailed price information for Eledon Pharmaceuticals Inc (ELDN-Q) from The Globe and Mail including charting and trades.

Positive results from a Phase 1 study evaluating the tolerability and pharmacokinetics of TNX-1500, a next generation anti-CD40L mAb for prevention of kidney transplant rejection, support ...